knowledge -WSS

knowledge

author：hotspot 2025-10-01 21:48:39 - browse：252

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Information blocking fines are now fair game in health care

WSS

Young boy dies in trial for Pfizer Duchenne gene therapy

Covid’s new normal has set in amid another rise in cases

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Senate bill would ban some hospital facility fees

FDA weighs limits of animal data in assessing artificial wombs

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

focus

knowledge

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

First Opinion on colorectal cancer screening: letter and response

Medicare proposal to cover medical devices draws a mixed reaction

Information blocking fines are now fair game in health care

In age of alternative facts, a scholarly course on calling out crap

'A game

As demand for Covid shots wanes, Moderna seeks its next success

FDA panel to weigh safety of artificial wombs for preterm births

Virginia high school admissions case could be legal follow

David Liu startup to focus on CRISPR delivery

knowledge

Covid’s new normal has set in amid another rise in cases

Overprescribed: High cost isn't America's only drug problem

Researchers test human milk's ability to repair gut microbiome

UnitedHealth, in a surprise, takes aim at Steward’s physician group

FDA panel to weigh safety of artificial wombs for preterm births

Drug companies' payments and gifts affect physicians' prescribing

entertainment

leisure time

focus

entertainment